FindTrial
Sign In

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00437151
Enrollment
61
Registered
2007-02-19
Start date
2006-06-30
Completion date
2007-06-30
Last updated
2022-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Brief summary

The primary objective of this study is to investigate potential differences in treatment adherence by teenagers among four interventions during treatment for acne.

Detailed description

Same as above.

Interventions

OTHERMore frequent than normal office visits

Mode of patient reminder

OTHERElectronic reminders (voice, e-mail, text messages)

Mode of patient reminder

OTHERParenteral involvement / intervention reminders

Mode of patient reminder

OTHERNo intervention or reminders

Mode of patient reminder

Sponsors

Galderma R&D
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
13 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Adolescent subjects with a diagnosis of moderate to severe Acne vulgaris

Exclusion criteria

* Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring more than topical treatment (e.g. oral isotretinoin)

Design outcomes

Primary

MeasureTime frame
Efficacy - Percent adherence calculated from MEMS Caps readings12 weeks

Secondary

MeasureTime frame
Efficacy - lesion counts; percent adherence as calculated by product weights and by Subject's Diary; Global Severity Assessment; Global Assessment of Improvement; Subject questionnaire12 weeks
Safety - tolerability and adverse event reporting12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026